Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 29:9:2810.
doi: 10.3389/fimmu.2018.02810. eCollection 2018.

Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity

Affiliations
Review

Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity

Aleksey Molodtsov et al. Front Immunol. .

Abstract

Resident memory (TRM) cells are a distinct tissue-localized T cell lineage that is crucial for protective immunity in peripheral tissues. While a great deal of effort has focused on defining their role in immunity to infections, studies now reveal TRM cells as a vital component of the host immune response to cancer. Characterized by cell-surface molecules including CD103, CD69, and CD49a, TRM-like tumor-infiltrating lymphocytes (TILs) can be found in a wide range of human cancers, where they portend improved prognosis. Recent studies in mouse tumor models have shown that TRM cells are induced by cancer vaccines delivered in peripheral tissue sites, or by the depletion of regulatory T cells. Such tumor-specific TRM cells are recognized as both necessary and sufficient for long-lived protection against tumors in peripheral tissue locations. TRM responses against tumor/self-antigens can concurrently result in the development of pathogenic TRM responses to self, with a growing number of autoimmune diseases and inflammatory pathologies being attributed to TRM responses. This review will recount the path to discovering the importance of resident memory CD8 T cells as they pertain to cancer immunity. In addition to highlighting key studies that directly implicate TRM cells in anti-tumor immunity, we will highlight earlier work that implicitly suggested their importance. Informed by studies in infectious disease models, and instructed by a clear role for TRM cells in autoimmunity, we will discuss strategies for therapeutically promoting TRM responses in settings where they don't naturally occur.

Keywords: CD103; TCM; TIL; TRM; biomarker; immunotherapy; melanoma; vitiligo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Atlas of TRM responses in peripheral tissues and tumors. CD8+ TRM cells occupy a diverse array of tissues and tumors. For each tissue location, gray boxes indicate: (1) tumor types in which TRM-like TILs have been identified (orange), (2) infections that give rise to TRM responses (red), and (3) autoimmune or inflammatory conditions in which TRM cells have been identified (green).
Figure 2
Figure 2
Skin resident-memory T cell responses to melanoma in the context of autoimmune vitiligo. Tumor-specific TRM precursor populations are recruited from circulation into the skin by chemokine signals. Following entrance into the skin, these T cells kill melanocytes, develop into TRM cells, and produce IFN-γ. Tumor-specific TRM cells populate the dermis, epidermis, and hair follicles, where IL-15 is produced. CD103-dependent TRM cells mediate the durable recall response to melanoma in the dermis.

References

    1. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J. (1957) 1:779–86. 10.1136/bmj.1.5022.779 - DOI - PMC - PubMed
    1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21:137–48. 10.1016/j.immuni.2004.07.017 - DOI - PubMed
    1. Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol. (2018) 9:14. 10.3389/fimmu.2018.00014 - DOI - PMC - PubMed
    1. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist (2008) 13(Suppl. 4):2–9. 10.1634/theoncologist.13-S4-2 - DOI - PubMed
    1. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. (2018) 8:1069–86. 10.1158/2159-8290.CD-18-0367 - DOI - PubMed

Publication types